Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.
In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.
About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.
Read the full story: http://hcp.lv/K6a9Bp